ReleaseWire Connect

Diabetes mellitus is one of the most widely prevalent endocrine disorder of carbohydrate metabolism. Over the last couple of years, there has been a significant rise in diabetes mellitus cases worldwide. Sedentary lifestyle coupled with unhealthy dietaries leads to obesity which in turn is fueling diabetic cases. Glucose sensors is a compact analytical device or a unit incorporating a biological or biologically derived sensitive recognition element integrated with physiochemical transducer. Self-monitoring blood glucose investigated in diabetes mellitus is essential for insulin treatment or oral glucose lowering medication to provide information of glucose concentrations in our body. These sensors has proved quite efficient in monitoring the glucose level in human body, thus gaining wide popularity among healthcare practitioners for assessment purpose.

Drug delivery system is the process of administering therapeutic substance through common route of administration to achieve a therapeutic effect in humans or animals. Drugs release the active ingredients in the target area so that in the period of time it controls though its formulation. The most important driving factor for drug delivery technology market is the increasing demand for effective delivery mechanisms of novel biopharmaceuticals.

Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud's phenomenon, livedo reticularis, thrombosis, and myositis. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening severity. It is also called as drug-induced lupus erythematosus due to common observation against drugs such as isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE. While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug in SLE because of the multiple beneficial effects of this agent.

Widespread acceptance of liquid biopsy technique in North America and steady adoption in developing regions is expected to drive global liquid biopsy market revenues. The global market is expected to reach US$ 407 Mn in 2016, up from US$ 351 Mn in 2015. North America will continue to remain the largest market for liquid biopsy, accounting for over 50% share of the global market.

The global special purpose needles market is projected to be valued at US$ 17,261.5 million by the end of 2026, registering a CAGR of 7.4% during the forecast period (2016–2026). In a new report titled "Special Purpose Needles Market: Global Industry Analysis and Opportunity Assessment, 2016–2026", Future Market Insights delivers key insights on the factors and trends impacting the global special purpose needles market over a 10-year forecast period (2016–2026).

The global industrial microbiology market is expected to witness a y-o-y growth of 6.7% in 2016 over 2015 and reach US$ 9.46 Bn in revenues. North America will continue to be the most lucrative market, accounting for over 25% of the market share.

The global excimer and femtosecond ophthalmic lasers market is expected to witness stable growth in 2016, reaching a value of US$ 666 Mn in terms of revenues. Excimer laser systems will continue to outsell femtosecond lasers. North America will remain the top market, whereas Asia Pacific (excluding China and Japan) is anticipated to create a lucrative market for excimer and femtosecond ophthalmic lasers globally.

Anti-ageing products and services continue to witness steady growth, with global revenues poised to reach US$ 151.8 Bn in 2016, a growth of 7.7% over 2015. Generation X (born between early 60s to mid-70s) will continue to be the key consumer segment, with global demand from this consumer segment anticipated to reach US$ 66,099.3 Mn by the end of this year. The impact of the global 'health and wellness' trend has gained further momentum in 2016, with leading brands incorporating concepts of healthy ageing in their products and services.

Continuous peripheral nerve block catheters are gaining traction in the healthcare sector as an effective analgesic for pain management. The global market for continuous peripheral never block catheters (CPNBC) was valued at US$ 372.8 Mn in 2015, and is expected to witness a year-over-year growth of 4.9% to reach US$ 391.2 Mn in 2016.

Global endoscope reprocessing device market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by growing geriatric population, increasing number of Endoscope surgeries and development of automated endoscope reprocessor and techniques. According to the new report, "Endoscope Reprocessing Device Market: Global Industry Analysis (2012–2016) and Opportunity Assessment (2017–2027)," which has been published by Future Market Insights for the projected period of 10-years, i.e. during 2017 to 2027, the endoscope reprocessing device market in MEA is expected to record comparatively less growth due to low awareness about infection control and less availability of reprocessor. The global endoscope reprocessing device market to grow from US$ 949.9 Mn in 2016 to US$ 2,171.5 Mn by 2027 end. This represents CAGR of 7.9% over the forecast period of 2017–2027